Optic neuritis: current challenges in diagnosis and management
暂无分享,去创建一个
[1] N. Newman,et al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment , 2022, The Lancet Neurology.
[2] F. Costello,et al. A Practical Approach to the Diagnosis and Management of Optic Neuritis , 2022, Annals of Indian Academy of Neurology.
[3] T. Chitnis,et al. Positive Predictive Value of MOG-IgG for Clinically Defined MOG-AD Within a Real-World Cohort , 2022, Frontiers in Neurology.
[4] Jacqueline Palace,et al. Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. , 2022, JAMA neurology.
[5] S. Saidha,et al. OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. , 2022, Multiple sclerosis and related disorders.
[6] À. Rovira,et al. Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. , 2021, Multiple sclerosis and related disorders.
[7] Ethan Meltzer,et al. Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist , 2021, Current Rheumatology Reports.
[8] B. Weinshenker,et al. Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing , 2021, JAMA neurology.
[9] J. Bennett,et al. The changing landscape of optic neuritis: a narrative review , 2021, Journal of Neurology.
[10] Jacqueline Palace,et al. New therapies for neuromyelitis optica spectrum disorder , 2020, The Lancet Neurology.
[11] F. Paul,et al. Neuromyelitis optica , 2020, Nature Reviews Disease Primers.
[12] A. Kermode,et al. Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy. , 2020, Multiple sclerosis and related disorders.
[13] F. Paul,et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients , 2020, Journal of Neuroinflammation.
[14] D. Hodge,et al. Population based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. , 2020, American journal of ophthalmology.
[15] O. Ciccarelli,et al. Treatment of MOG antibody associated disorders: results of an international survey , 2020, Journal of Neurology.
[16] B. Weinshenker,et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder , 2020, Neurology.
[17] Jacqueline Palace,et al. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. , 2020, Multiple sclerosis and related disorders.
[18] Paul P. Lee,et al. Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis , 2020, JAMA Network Open.
[19] A. Traboulsee,et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial , 2020, The Lancet Neurology.
[20] Chunshui Yu,et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial , 2020, The Lancet Neurology.
[21] T. Misu,et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial , 2020, The Lancet Neurology.
[22] N. Newman. The Optic Neuritis Treatment Trial. , 2020, Ophthalmology.
[23] Jacqueline Palace,et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.
[24] John J. Chen,et al. Clinical Characteristics and Treatment of MOG-IgG–Associated Optic Neuritis , 2019, Current Neurology and Neuroscience Reports.
[25] Gary R Cutter,et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial , 2019, The Lancet.
[26] Ashwini Hiremath,et al. Plasma Exchange as a First Line Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorders , 2019, Annals of Indian Academy of Neurology.
[27] Tiansong Zhang,et al. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis. , 2019, Multiple sclerosis and related disorders.
[28] O. Mimura,et al. Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan. , 2019, Ophthalmology.
[29] J. Kira,et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD , 2019, Neurology.
[30] M. Bach,et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? , 2019, Neurology: Neuroimmunology & Neuroinflammation.
[31] Jacqueline Palace,et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.
[32] D. Wingerchuk. Disease-modifying therapies should be stopped in NMOSD patients in remission – Commentary , 2019, Multiple sclerosis.
[33] J. Mills,et al. A multicenter comparison of MOG-IgG cell-based assays , 2019, Neurology.
[34] J. P. Ospina,et al. Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. , 2019, Multiple sclerosis and related disorders.
[35] D. Sato,et al. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis , 2018, Multiple sclerosis.
[36] B. Weinshenker,et al. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. , 2018, American journal of ophthalmology.
[37] Fiona Costello,et al. The role of optical coherence tomography in neuro-ophthalmology , 2018 .
[38] J. A. Fraser,et al. Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial , 2018, JAMA neurology.
[39] F. Costello,et al. Transient vision loss: a neuro-ophthalmic approach to localizing the diagnosis , 2018 .
[40] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[41] N. Kung,et al. Incidence and Causes of Overdiagnosis of Optic Neuritis , 2018, JAMA ophthalmology.
[42] P. Cabre,et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[43] V. Shaygannejad,et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial , 2017, Journal of Neurology.
[44] K. Fujihara,et al. Neuromyelitis Optica Spectrum Disorders. , 2017, Neuroimaging clinics of North America.
[45] D. Wingerchuk,et al. Transient smartphone blindness: Relevance to misdiagnosis in neurologic practice , 2017, Neurology.
[46] Lynn D. Hudson,et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis , 2017, Multiple sclerosis.
[47] V. Lennon,et al. Clinical utility of testing AQP4-IgG in CSF , 2016, Neurology: Neuroimmunology & Neuroinflammation.
[48] J. Joo,et al. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints , 2016, Multiple sclerosis.
[49] D. Reich,et al. Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis , 2016, American Journal of Neuroradiology.
[50] F. Paul,et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses , 2016, Annals of neurology.
[51] J. Joo,et al. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. , 2015, JAMA neurology.
[52] A. Traboulsee,et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.
[53] Jacqueline Palace,et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography , 2015, Multiple sclerosis.
[54] S. Galetta,et al. Analysis of the treatment of neuromyelitis optica , 2015, Journal of the Neurological Sciences.
[55] Jacqueline A Palace,et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. , 2014, JAMA neurology.
[56] J. Horton,et al. Microcysts in the inner nuclear layer from optic atrophy are caused by retrograde trans-synaptic degeneration combined with vitreous traction on the retinal surface. , 2013, Brain : a journal of neurology.
[57] G. Plant,et al. Distinguishing Optic Neuritis in Neuromyelitis Optica Spectrum Disease From Multiple Sclerosis: A Novel Magnetic Resonance Imaging Scoring System , 2013, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[58] A. McKinney,et al. Accuracy of routine fat-suppressed FLAIR and diffusion-weighted images in detecting clinically evident acute optic neuritis , 2013 .
[59] N. Volpe. The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results. , 2008, Archives of ophthalmology.
[60] Melvin Greer,et al. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. , 2008, Archives of neurology.
[61] Y. Itoyama,et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis , 2007, Multiple sclerosis.
[62] Ichiro Nakashima,et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.
[63] J. Corbett. Experience of the optic neuritis treatment trial , 2004, Current Neurology and Neuroscience Reports.
[64] M. Kupersmith,et al. Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. , 2002, Brain : a journal of neurology.
[65] A. Vighetto,et al. [Inflammatory optic neuropathies]. , 2001, La Revue du praticien.
[66] Chris A. Johnson,et al. Comparison of central and peripheral visual field properties in the optic neuritis treatment trial. , 1996, American journal of ophthalmology.
[67] R. Beck,et al. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. , 1994, Ophthalmology.
[68] Neil R. Miller,et al. A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis , 1992 .
[69] The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. , 1991, Archives of ophthalmology.
[70] V. Lennon,et al. Clinical utility of testing AQP4-IgG in CSF , 2016, Neurology: Neuroimmunology & Neuroinflammation.